Compare Nu Holdings Ltd (NU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Viatris Inc — how do they compare? Nu Holdings Ltd trades at $14.39 (market cap $67.58B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Nu Holdings Ltd is far larger — about 3.4× Viatris Inc's market cap, and Viatris Inc pays a 2.83% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| NU | VTRS | |
|---|---|---|
Market Cap | $67.58B | $19.79B |
Sector | Financials | Health |
52-Week High | $18.76 | $17.39 |
52-Week Low | $11.60 | $8.74 |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $14.39, up 5.89% in the last session, with a bullish technical signal from moving averages and strong fundamental growth. Revenue surged from $3.0B in 2022 to $10.63B in 2025, while net income turned positive to $2.87B. Recent news highlights expansion in Brazil and Mexico, including a new banking license, supporting continued growth momentum.
Outlook remains positive with a consensus price target of $14.98, though risks include rapid credit expansion and increased provisions. The stock offers exposure to Latin America's digital banking growth but faces execution risks in new markets and competitive pressures. Analyst sentiment is bullish with 55% buy ratings.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
